De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation
De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation
复制标题
DOI：
10.1016/j.joms.2005.08.018
复制
发表时间：
2005-12-01
影响因子：
1.9
通讯作者：
Triplett, RG
中科院分区：
文献类型：
--
作者：
Boyne, PJ;Lilly, LC;Triplett, RG
目的：这项11期研究旨在评估2种浓度的重组人骨形态发生蛋白-2（rhBMP-2）在需要分期上颌窦底提升的患者中诱导骨内牙种植体所需骨的安全性和有效性。患者接受rhBMP-2治疗（通过可吸收胶原海绵[ACS]），浓度为0.75 mg/mL（n = 18），1.50 mg/mL（n = 17），或与骨移植物（n = 13）。通过治疗前和治疗后4个月以及牙种植体功能负荷后6个月的计算机断层扫描测量牙槽嵴高度、宽度和密度来评估骨诱导结果：治疗后4个月，各组牙槽嵴高度的平均增加相似;骨移植物、0.75 mg/mL和1.50 mg/mL rhBMP-2/ACS治疗组分别为11.3 mm、9.5 mm和10.2 mm。治疗组间牙槽嵴宽度（颊侧至舌侧）的平均增加有统计学差异;植骨组、0.75 mg/mL和1.50 mg/mL治疗组分别为4.7 mm、2.0 mm和2.0 mm（P
Purpose: This phase 11 study was designed to evaluate 2 concentrations of recombinant human bone morphogenetic protein-2 (rhBMP-2) for safety and efficacy in inducing adequate bone for endosseous dental implant in patients requiring staged maxillary sinus floor augmentation.Materials and Methods: Patients were treated with rhBMP-2 (via an absorbable collagen sponge [ACS]), at concentrations of 0.75 mg/mL (n = 18), 1.50 mg/mL (n = 17), or with bone graft (n = 13). Bone induction was assessed by alveolar ridge height, width, and density measurements from computed tomography scans obtained before and 4 months after treatment and 6 months post-functional loading of dental implants (density only).Results: Mean increases in alveolar ridge height at 4 months after treatment were similar among the groups; 11.3 mm, 9.5 mm, and 10.2 mm, respectively, in the bone graft, 0.75 mg/mL, and 1.50 mg/mL rhBMP-2/ACS treatment groups. Mean increases in alveolar ridge width (buccal to lingual) at the crest of the ridge were statistically different among the treatment groups; 4.7 mm, 2.0 mm, and 2.0 mm, respectively, in the bone graft, 0.75 mg/mL, and 1.50 mg/mL treatment groups (P